Roivant Sciences (ROIV) Times Interest Earned (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Times Interest Earned came in at -$4639.9 in Q3 2025, down 156050.86% YoY from N/an in Q3 2024, and down 199.64% on a QoQ basis from -$1548.5 in Q2 2025.
Roivant Sciences (ROIV) Times Interest Earned (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Times Interest Earned data on file, last reported at -$4639.9 in Q3 2025.
- Quarterly Times Interest Earned fell 156050.86% year-over-year to -$4639.9 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$25018.1 (down 64469.86% YoY) and the FY2026 annual result came in at -$0.32, up 77.46% from the prior year.
- Times Interest Earned fell to -$4639.9 in Q3 2025, from -$1548.5 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $185.76 in Q4 2023 to a low of -$4639.9 in Q3 2025.
- A 5-year average of -$462.14 and a median of -$26.86 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned jumped 482.76% — and 2025, when it slumped 156050.86%.
- Tracing ROIV's Times Interest Earned over 5 years: stood at -$194.9 in 2021, then jumped by 75.1% to -$48.53 in 2022, then jumped by 482.76% to $185.76 in 2023, then slumped by 103.42% to -$6.35 in 2024, then tumbled by 73019.14% to -$4639.9 in 2025.
- The last three Times Interest Earned figures came in at -$4639.9 (Q3 2025), -$1548.5 (Q2 2025), and -$6.35 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -55.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.73 |
| Sep 30, 2025 | -4,639.89 |
| Jun 30, 2025 | -1,548.49 |
| Dec 31, 2024 | -6.35 |
| Sep 30, 2024 | -2.97 |
| Jun 30, 2024 | -1.26 |
| Dec 31, 2023 | 185.76 |
| Sep 30, 2023 | -23.00 |
| Jun 30, 2023 | -28.93 |
| Dec 31, 2022 | -48.53 |
| Sep 30, 2022 | -24.80 |
| Jun 30, 2022 | -23.80 |
| Dec 31, 2021 | -194.90 |
| Sep 30, 2021 | -51.34 |
| Jun 30, 2021 | -61.44 |
| Dec 31, 2020 | -351.52 |
| Sep 30, 2020 | -257.47 |
| Jun 30, 2020 | -144.69 |